Last 8 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.95 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 0.61 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | 0.31 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Pelthos Therapeutics Inc.'s operating margin was -207.4% in Q3 2025.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 54.3% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -207.4% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -219.3% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -62.7% | — | — | — | — | -373.9% | -226.7% | — |
| — | — | — | — | — | — | — | — | — | |
| ROA | -1085.7% | -25.5% | -397.8% | -172.6% | -109.8% | -71.5% | -53.4% | -124.1% | -4190.4% |
| — | +64.3% | -644.9% | -39.0% | +97.4% | — | — | — | — | |
| ROIC | — | -53.3% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 230.1% YoY to 1.98x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.06 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.34 | 1.98 | 0.11 | 0.18 | 0.34 | 0.60 | 0.93 | 1.39 | 0.01 |
| — | +230.1% | -88.0% | -87.2% | +2175.3% | — | — | — | — | |
| Quick Ratio | 0.34 | 1.01 | 0.11 | 0.18 | 0.34 | 0.60 | 0.93 | 1.39 | 0.01 |
| — | +68.0% | -88.0% | -87.2% | +2175.3% | — | — | — | — | |
| Interest Coverage | -9.63 | -11.41 | -14.78 | -13.72 | -16.90 | -52.50 | -159.50 | -3.08 | -24.19 |
| — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPelthos Therapeutics Inc.'s current P/E is -1.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pelthos Therapeutics Inc.'s business trajectory between earnings reports.